During Thursday’s Morning trade, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), gained 4.96% to $2.54.
Today, Advanced Micro Devices, unveiled innovation in heterogeneous high performance computing (HPC) by delivering more than 1.5 petaFLOPS of AMD FirePro™ S9150 server GPU performance for the Next Generation Sequencing Centre (NGSC) at the Centre of New Technologies, University of Warsaw in support of bioinformatics research related to next generation sequencing (NGS) studies. The new ORION cluster features 150 Dell PowerEdge R730 servers with two AMD FirePro S9150 server GPUs, for a total GPU peak of 1.52 petaFLOPS single precision and 0.76 petaFLOPS double precision performance1. The energy-efficient cluster enables high speed and efficient calculations for genomic data, applicable to a range of genomics and bioinformatics studies, using a fast and power efficient OpenCL™ implementation for research applications.
“We’re committed to building our HPC leadership position in the industry as a foremost provider of computing applications, tools and technologies,” said Sean Burke, corporate vice-president and general manager, AMD Professional Graphics. “This installation reaffirms AMD’s leading role in HPC with the implementation of the AMD FirePro S9150 server GPUs in this 1.5 petaFLOPS supercomputer cluster. AMD and Dell are enabling OpenCL™ applications for critical science research usage for this cluster. AMD is proud to collaborate with Dell and NGSC to support such important life science and computer science research.”
“We had excellent cooperation with Dell and AMD to make this project happen in such a short timeframe,” said Dr. Krzysztof Ginalski, head of the Next Generation Sequencing Centre and Laboratory of Bioinformatics and Systems Biology at the Centre of New Technologies, University of Warsaw. “The state-of-the-art technology and industry-leading systems administration capabilities in the Dell PowerEdge R730 servers together with the AMD FirePro S9150 server graphics deliver an extremely powerful basis for the ORION cluster and provide the compute capabilities we need for our research. The large 16GB of memory of the AMD FirePro S9150 server graphics allows us to run advanced bioinformatics computations on one GPU without inter-GPU communication resulting in very efficient operations. We have chosen a multi-GPU approach with two GPU boards per server to enable cost- and energy-efficient configuration.”
“Dell is passionate about the HPC market and committed to powering the revolutionary discoveries being made by top research organizations and enterprise around the world,” said Ravi Pendekanti, vice president, product administration, Dell Server Solutions. “Together, Dell and AMD have reached a new level with the NGSC project, revealing the true power of the Dell PowerEdge R730 with AMD FirePro S9150 GPUs. There is no doubt that our joint NGSC project delivers top-tier performance for critical HPC applications, while also providing major energy efficiencies.”
“We are proud that we had opportunity to build this HPC cluster for NGSC,” said Michał Bieńkowski, chief executive officer at Slash sp. z o. o. “Our strong cooperation with Dell and AMD gave us the ability to deliver an effective solution in a very short time. We entered the HPC market several years ago offering high performance solutions in Poland’s education field. Our aim is to build fast, reliable and energy-saving data center systems.”
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), inclined 4.49% to $9.51, during its current trading session, hitting its highest level.
Synergy Pharmaceuticals, declared that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
Finally, Health Net, Inc. (NYSE:HNT), gained 12.22%, and is now trading at $73.01, hitting its highest level.
Cognizant (CTSH) offered an update on the status of its relationship with Health Net, Inc. (HNT) and reaffirmed its 2015 guidance following the declaration that Health Net has reached a contract to be attained by Centene Corporation (CNC).
Health Net Relationship
“Today’s declaration by Health Net and Centene is yet another example of how the healthcare landscape is rapidly changing, with increasing focus on medical costs, consumerization and a changing regulatory environment driving consolidation in addition to an ongoing search for solutions that fundamentally change the business model and economics of healthcare administration,” said Gordon Coburn, President, Cognizant. “As we congratulate Health Net and Centene today, we look forward to ongoing to partner with them to support their technology and operations requirements.”
Key updates on the relationship comprise:
- Cognizant remains a key planned technology and operations partner to Health Net, with the existing relationship being extended through the end of 2020 with a total contract value of about $520 million. This will provide ongoing support of critical Health Net applications and processes.
- The planned implementation of a seven-year master services agreement for end-to-end administrative services between Cognizant and Health Net, first declared in August 2014 and planned to start in mid-2015, is being deferred while Health Net and Centene complete the merger review and approval process. Cognizant anticipates that if the merger of Health Net and Centene is accomplished, the existing master services agreement will not be implemented as there will likely be overlaps in services and capabilities planned to be offered by Cognizant.
- Cognizant has negotiated the right to license certain Health Net intellectual property for incorporation into its healthcare administration solutions and as-a-service platforms.
Health Net, Inc. provides managed health care services through health plans and government-sponsored managed care plans in the United States. It operates through Western Region Operations and Government Contracts segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
